Medicines developer and producer Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA) will pursue a new strategic focus in the Japanese market, the company announced on Thursday.
Nearly five years after it was established, Teva's joint business venture with Takeda in Japan will shift its focus to commercialising a selection of complex generics, specialty assets and other pipeline opportunities.
In conjunction with this decision, the Japanese business venture has agreed to divest the majority of its generic and operational assets to Nichi-Iko Pharmaceutical Co Ltd. This transaction is expected to be completed by early 2021.
The business venture will retain approximately 20% of its molecules and several pipeline assets, as well as its portfolio of authorised generics, LLPs and specialty assets.
"For Teva, and in line with the company's strategic objectives, the new model presents a chance to drive better performance by focusing our Japan business on a portfolio of select generics and pipeline of specialty assets, while continuing to put patients and healthcare professionals at the centre of our strategy," said Gianfranco Nazzi, Teva's executive vice president of International Markets Commercial.
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS